Jesse D Troy1, Heather R Hill2, Marian G Ewell3, Sharon E Frey4. 1. The EMMES Corporation, 401 North Washington Street, Suite 700, Rockville, MD 20850, United States. Electronic address: jesse.troy@duke.edu. 2. The EMMES Corporation, 401 North Washington Street, Suite 700, Rockville, MD 20850, United States. Electronic address: hhill@emmes.com. 3. The EMMES Corporation, 401 North Washington Street, Suite 700, Rockville, MD 20850, United States. Electronic address: mewell@emmes.com. 4. Saint Louis University School of Medicine, Department of Internal Medicine, Edward A. Doisy Research Center, 1100 S. Grand Bld., Saint Louis, MO 63104, United States. Electronic address: freyse@slu.edu.
Abstract
INTRODUCTION: Previous research shows immune response to vaccination differs by sex but this has not been explored for IMVAMUNE, a replication-deficient smallpox vaccine developed in response to the potential for bioterrorism using smallpox. METHODS: We conducted a participant-level meta-analysis (N=275, 136 men, 139 women) of 3 randomized trials of IMVAMUNE conducted at 13 centers in the US through a federally-funded extramural research program. Studies were eligible for inclusion if they tested the standard dose (1×10(8)TCID₅₀/mL on Days 0 and 28) of liquid formulation IMVAMUNE, were completed at the time of our search, and enrolled healthy vaccinia-naïve participants. Models of the peak log₂ ELISA and PRNT titers post-second vaccination were constructed for each study with sex as a covariate. Results from these models were combined into random effects meta-analyses of the sex difference in response to IMVAMUNE. We then compared this approach with fixed effects models using the combined participant level data. RESULTS: In each study the mean peak log₂ ELISA titer was higher in men than women but no single study demonstrated a statistically significant difference. Combination of the adjusted study-specific estimates into the random effects model showed a higher mean peak log₂-titer in men compared with women (absolute difference [men-women]: 0.32, 95% CI: 0.02-0.60). Fixed effects models controlling for study showed a similar result (log₂ ELISA titer, men-women: 0.34, 95% CI: 0.04-0.63). This equates to a geometric mean peak titer that is approximately 27% higher in men than women (95% CI: 3-55%). Peak log₂ PRNT titers were also higher (although not significantly) in men (men-women: 0.14, 95% CI: -0.30 to 0.58). CONCLUSION: Our results show statistically significant differences in response to IMVAMUNE comparing healthy, vaccinia-naïve men with women and suggest that sex should be considered in further development and deployment of IMVAMUNE and other MVA-based vaccines.
INTRODUCTION: Previous research shows immune response to vaccination differs by sex but this has not been explored for IMVAMUNE, a replication-deficient smallpox vaccine developed in response to the potential for bioterrorism using smallpox. METHODS: We conducted a participant-level meta-analysis (N=275, 136 men, 139 women) of 3 randomized trials of IMVAMUNE conducted at 13 centers in the US through a federally-funded extramural research program. Studies were eligible for inclusion if they tested the standard dose (1×10(8)TCID₅₀/mL on Days 0 and 28) of liquid formulation IMVAMUNE, were completed at the time of our search, and enrolled healthy vaccinia-naïve participants. Models of the peak log₂ ELISA and PRNT titers post-second vaccination were constructed for each study with sex as a covariate. Results from these models were combined into random effects meta-analyses of the sex difference in response to IMVAMUNE. We then compared this approach with fixed effects models using the combined participant level data. RESULTS: In each study the mean peak log₂ ELISA titer was higher in men than women but no single study demonstrated a statistically significant difference. Combination of the adjusted study-specific estimates into the random effects model showed a higher mean peak log₂-titer in men compared with women (absolute difference [men-women]: 0.32, 95% CI: 0.02-0.60). Fixed effects models controlling for study showed a similar result (log₂ ELISA titer, men-women: 0.34, 95% CI: 0.04-0.63). This equates to a geometric mean peak titer that is approximately 27% higher in men than women (95% CI: 3-55%). Peak log₂ PRNT titers were also higher (although not significantly) in men (men-women: 0.14, 95% CI: -0.30 to 0.58). CONCLUSION: Our results show statistically significant differences in response to IMVAMUNE comparing healthy, vaccinia-naïve men with women and suggest that sex should be considered in further development and deployment of IMVAMUNE and other MVA-based vaccines.
Authors: Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka Journal: Nat Med Date: 2003-08-17 Impact factor: 53.440
Authors: Mike M Pütz; Isabella Alberini; Claire M Midgley; Ilaria Manini; Emanuele Montomoli; Geoffrey L Smith Journal: J Gen Virol Date: 2005-11 Impact factor: 3.891
Authors: Stephanie Gallwitz; Ted Schutzbank; Richard L Heberling; S S Kalter; Jeffrey E Galpin Journal: J Clin Microbiol Date: 2003-09 Impact factor: 5.948
Authors: Dennis D Taub; William B Ershler; Mark Janowski; Andrew Artz; Michael L Key; Julie McKelvey; Denis Muller; Bernard Moss; Luigi Ferrucci; Patricia L Duffey; Dan L Longo Journal: Am J Med Date: 2008-12 Impact factor: 4.965
Authors: Richard B Kennedy; Gregory A Poland; Inna G Ovsyannikova; Ann L Oberg; Yan W Asmann; Diane E Grill; Robert A Vierkant; Robert M Jacobson Journal: Vaccine Date: 2016-05-11 Impact factor: 3.641
Authors: Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Diane E Grill; Gregory A Poland Journal: Vaccine Date: 2021-12-21 Impact factor: 3.641
Authors: Eric M Mucker; Suzanne E Wollen-Roberts; Adrienne Kimmel; Josh Shamblin; Darryl Sampey; Jay W Hooper Journal: PLoS Negl Trop Dis Date: 2018-06-21
Authors: Julia A Tree; Graham Hall; Peter Rees; Julia Vipond; Simon G P Funnell; Allen D Roberts Journal: Hum Vaccin Immunother Date: 2016-07-02 Impact factor: 3.452